Skip To Content

Study ID: COG AALL1131

Title:

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Location:
Sioux Falls Region
Principal Investigator:
Kayelyn Wagner, MD
Disease:
ALL (Acute Lymphocytic Leukemia)
Stage:
Phase III
Status:
Active - Partially Closed to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.